Assessment and treatment of breakthrough cancer pain: from theory to clinical practice

References

• BrueraEFainsingerRMacEachernTHansonJThe use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary reportPain199250175771381072
   PubMed Web of Science ®Google Scholar
• CaraceniAMartiniCZeccaEWorking Group of an IASP Task Force on Cancer PainBreakthrough pain characteristics and syndromes in patients with cancer pain. An international surveyPalliat Med200418317718315198130
   PubMed Web of Science ®Google Scholar
• DaviesABuchananAZeppetellaGBreakthrough cancer pain: an observational study of 1000 European oncology patientsJ Pain Symptom Manage201346561962823523361
   PubMed Web of Science ®Google Scholar
• GrecoMTCorliOMontanariMWriting Protocol CommitteeCancer Pain Outcome Research Study Group (CPOR SG) InvestigatorsEpidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study GroupClin J Pain201127191820842024
   PubMed Web of Science ®Google Scholar
• VellucciRBreakthrough cancer painEur J Oncol201520suppl 11112
   Google Scholar
• AbernethyAPWheelerJLFortnerBVA health economic model of breakthrough painAm J Manag Care2008145 suppl 1S129S14018611101
   PubMedGoogle Scholar
• BedardGDaviesAMcDonaldRBreakthrough cancer pain: a comparison of surveys with European and Canadian patientsSupport Care Cancer201523379179625193599
   PubMed Web of Science ®Google Scholar
• PortenoyRKHagenNABreakthrough pain: definition, prevalence and characteristicsPain19904132732811697056
   PubMed Web of Science ®Google Scholar
• MercadanteSRadbruchLCaraceniASteering Committee of the European Association for Palliative Care (EAPC) Research NetworkEpisodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative CareCancer200294383283911857319
   PubMed Web of Science ®Google Scholar
• DaviesANDickmanAReidCStevensAMZeppetellaGScience Committee of the Association for Palliative Medicine of Great Britain and IrelandThe management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and IrelandEur J Pain200913433133818707904
   PubMed Web of Science ®Google Scholar
• DaviesAZeppetellaGAndersenSMulti-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategiesEur J Pain201115775676321251860
   PubMed Web of Science ®Google Scholar
• ZeppetellaGBreakthrough pain in cancer patientsClin Oncol2011236393398
   PubMed Web of Science ®Google Scholar
• MercadanteSLazzariMRealeCIOPS Study GroupItalian Oncological Pain Survey (IOPS): a multicentre Italian study of breakthrough pain performed in different settingsClin J Pain201531321422125654429
   PubMed Web of Science ®Google Scholar
• LøhreETKlepstadPBennettMIEuropean Association for Palliative Care Research Network. From “breakthrough” to “episodic” cancer pain? A European Association for Palliative Care Research Network Expert Delphi Survey toward a common terminology and classification of transient cancer pain exacerbationsJ Pain Symptom Manage20165161013101926921493
   PubMed Web of Science ®Google Scholar
• WebberKDaviesANCowieMRAccuracy of a diagnostic algorithm to diagnose breakthrough cancer pain as compared with clinical assessmentJ Pain Symptom Manage201550449550026025280
   PubMed Web of Science ®Google Scholar
• PerryGFThe Diagnosis and Treatment of Breakthrough PainNew YorkOxford American Pain Library2008
   Google Scholar
• ZeppetellaGRibeiroMDPharmacotherapy of cancer-related episodic painExpert Opin Pharmacother20034449350212667112
   PubMed Web of Science ®Google Scholar
• MercadanteSMaddaloniSRoccellaSSalvaggioLPredictive factors in advanced cancer pain treated only by analgesicsPain19925021511551408310
   PubMed Web of Science ®Google Scholar
• ZeppetellaGEvidence-based treatment of cancer-related break through pain with opioidsJ Natl Compr Canc Netw201311suppl 1S37S4323520185
   PubMed Web of Science ®Google Scholar
• JanjanNDo we need to improve pain management in the radiation oncology department?Nat Clin Pract Oncol2005213013116264903
   PubMedGoogle Scholar
• PignonTFernandezLAyassoSDurandMBadinandDCowenDImpact of radiation oncology practice on pain: a cross-sectional surveyInt J Radiat Oncol Biol Phys20046041204121015519793
   PubMed Web of Science ®Google Scholar
• MiserAWDothageJAWesleyRAMiserJSThe prevalence of pain in a pediatric and young adult cancer populationPain198729173833588002
   PubMed Web of Science ®Google Scholar
• ZeppetellaGDaviesAEijgelshovenIJansenJPA network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodesJ Pain Symptom Manage2014474772.e5785.e523981487
   PubMed Web of Science ®Google Scholar
• PoulainPMichenotNAmmarDMise au point sur l’utilisation du fentanyl transmuqueux chez le patient présentant des douleurs d’origine cancéreuseDouleurs2012133439
   Google Scholar
• CaraceniAHanksGKaasaSEuropean Palliative Care Research Collaborative (EPCRC)European Association for Palliative Care (EAPC)Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCLancet Oncol20121325868
   PubMed Web of Science ®Google Scholar
• AbrahmJLAssessing the patient in painAbrahmJLA Physician’s Guide to Pain and Symptom Management in Cancer Patients2nd edBaltimore, MDJohns Hopkins University Press2005107147
   Google Scholar
• RhinerMIVon GuntenCFCancer breakthrough pain in the presence of cancer-related chronic pain: fact versus perceptions of health-care providers and patientsJ Support Oncol20108623223821265388
   PubMedGoogle Scholar
• MercadanteSVellucciRCuomoALong-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer painSupport Care Cancer20152351349135425351457
   PubMed Web of Science ®Google Scholar
• VellucciRMediatiRDGasperoniSPharmacoeconomic considerations about breakthrough cancer painValue Health2015187A665A666
   Web of Science ®Google Scholar
• RuggeriMTurrizianiAOradeiMCost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer painExpert Rev Pharmacoecon Outcomes Res201414345946424702061
   PubMed Web of Science ®Google Scholar
• BennettDBurtonAWFishmanSConsensus panel recommendations for the assessment and management of breakthrough pain: Part 2 managementP and T2005306354361
   Google Scholar
• DarwishMKirbyMRobertsonPJrHellriegelEJiangJGComparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokineticsClin Pharmacokinetics2006458843850
   Web of Science ®Google Scholar
• ElsnerFZeppetellaGPorta-SalesJTagarroINewer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patientsClin Drug Investig2011319605618
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAFentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancerCNS Drugs201125651152221649451
   PubMed Web of Science ®Google Scholar
• ChristrupLLFosterDPopperLDTroenTUptonRPharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover studyClin Ther200830346948118405786
   PubMed Web of Science ®Google Scholar